U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT06833281) titled 'Extension Study of Participants From SPG302-ALZ-101' on Feb. 12.
Brief Summary: This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALZ-101 with mild to moderate Alzheimer's Disease (AD)
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Alzheimer's Disease
Intervention:
DRUG: SPG302
small synthetic molecule
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Spinogenix
Published by HT Digital Content Services with permission from Health Daily Digest....